Current Role of Magnetic Resonance Imaging in Prostate Cancer

被引：0
作者：
Mehralivand S. [1 ,2 ,3 ]
Sidana A. [2 ]
Maruf M. [2 ]
Choyke P.L. [3 ]
Pinto P.A. [2 ]
Turkbey B. [3 ,4 ]
机构：
[1] Department of Urology and Pediatric Urology, University Medical Center, Mainz
[2] Urologic Oncology Branch, NCI, NIH, Bethesda, MD
[3] Molecular Imaging Program, NCI, NIH, Bethesda, MD
[4] Molecular Imaging Program, National Cancer Institute, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, 20892-1088, MD
来源：
Current Radiology Reports | / 5卷 / 11期
关键词：
Active surveillance; Biopsy; Lesion detection; MRI; Prostate cancer; Staging;
D O I：
10.1007/s40134-017-0255-3
中图分类号：
学科分类号：
摘要：
Purpose of review: Multiparametric magnetic resonance imaging of the prostate (mpMRI) is a new rising diagnostic modality in prostate cancer management. The combination of anatomic and functional sequences allows for detection, localization, and characterization of prostate cancer lesions. This leads to shift from staging to other clinical applications. However, lack of standardization of scanning, detection, and reporting protocols is a major drawback. Recent findings: Current main applications of mpMRI are detection, staging, and localization with the latter one enabling targeted biopsies of MRI-detected lesions. With this approach, more clinically significant and less insignificant cancer lesions are detected. This technique has the potential to help solving the dilemma of overdiagnosis of indolent cancers and underdiagnosis of potentially aggressive cancers. The Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) is an attempt to establish more standardization in mpMRI. This new guideline could facilitate the clinical and scientific exchange among different institutions and therefore assist in gathering more multi-center evidence. Summary: Multiparametric magnetic resonance imaging of the prostate improves detection and staging of prostate cancer. In conjunction with targeted biopsy techniques, it allows for better characterization of the real tumor burden compared to template systematic biopsy. Potential future applications include active surveillance, detection of recurrence, metastasis and planning, and follow-up of focal therapy. © 2017, Springer Science+Business Media, LLC (Outside the USA).
引用
收藏
相关论文
共 67 条
[1]  
Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2016, CA Cancer J Clin, 66, 1, pp. 7-30, (2016)
[2]  
Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., Et al., Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 13, pp. 1310-1319, (2009)
[3]  
Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Et al., Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 13, pp. 1320-1328, (2009)
[4]  
Hamdy F.C., Donovan J.L., Lane J.A., Mason M., Metcalfe C., Holding P., Et al., 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 15, pp. 1415-1424, (2016)
[5]  
Hricak H., Williams R.D., Spring D.B., Moon K.L., Hedgcock M.W., Watson R.A., Et al., Anatomy and pathology of the male pelvis by magnetic resonance imaging, AJR Am J Roentgenol, 141, 6, pp. 1101-1110, (1983)
[6]  
Turkbey B., Pinto P.A., Mani H., Bernardo M., Pang Y., McKinney Y.L., Et al., Prostate cancer: value of multiparametric MR imaging at 3 T for detection–histopathologic correlation, Radiology, 255, 1, pp. 89-99, (2010)
[7]  
Turkbey B., Merino M.J., Gallardo E.C., Shah V., Aras O., Bernardo M., Et al., Comparison of endorectal coil and nonendorectal coil T2 W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology, J Magn Reson Imaging JMRI, 39, 6, pp. 1443-1448, (2014)
[8]  
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer, This study is the first larger prospective trial comparing targeted biopsy against systematic biopsy., (2015)
[9]  
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, (2017)
[10]  
Gupta R.T., Brown A.F., Silverman R.K., Tay K.J., Madden J.F., George D.J., Et al., Can radiologic staging with multiparametric MRI enhance the accuracy of the part in tables in predicting organ-confined prostate cancer?, Am J Roentgenol, 207, 1, pp. 87-95, (2016)
1234567